Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism

Journal of Hepatology

Volumn 50, Issue 5, 2009, Pages 969-979

  Giovannini, Catia ^a,b   Gramantieri, Laura ^a   Chieco, Pasquale ^a   Minguzzi, Manuela ^a   Lago, Federica ^a   Pianetti, Simona ^a   Ramazzotti, Eric ^a   Marcu, Kenneth B ^a,b,c   Bolondi, Luigi ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Doxorubicin; Hepatocellular carcinoma; Notch1; Notch3; p53; shRNA

Indexed keywords

DOXORUBICIN; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PROTEIN P53; RETROVIRUS VECTOR; SHORT HAIRPIN RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; HUMANS; LIVER NEOPLASMS; MALE; RECEPTOR, NOTCH1; RECEPTORS, NOTCH; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64549091858     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.032     Document Type: Article

References (30)

1. Qian J., Feng G.S., and Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 9 (2003) 1885-1891
2. Burden D.A., and Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400 (1998) 139-154
3. Artavanis-Tsakonas S., Rand M.D., and Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 284 (1999) 770-776
4. Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.L., Banks A., et al. Human ligands of the Notch receptor. Am J Pathol 154 (1999) 785-794
5. Yoneya T., Tahara T., Nagao K., Yamada Y., Yamamoto T., Osawa M., et al. Molecular cloning of delta-4, a new mouse and human Notch ligand. J Biochem 129 (2001) 27-34
6. Weinmaster G. The ins and outs of notch signaling. Mol Cell Neurosci 9 (1997) 91-102
7. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., et al. High-level coexpression of Jag1 and Notch1 Is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65 (2005) 8530-8537
8. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3 (2003) 565-576
9. Jundt F., Anagnostopoulos I., Forster R., Mathas S., Stein H., and Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplstic large cell lymphoma. Blood 99 (2002) 3398-3403
10. Nickoloff B.J., Osborne B.A., and Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 29 (2003) 6598-6608
11. Hu C., Dievart A., Lupien M., Calvo E., Tremblay G., and Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 168 (2006) 973-990
12. Qi R., An H., Yu Y., Zhang M., Liu S., Xu H., et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63 (2003) 8323-8329
13. Gramantieri L., Giovannini C., Lanzi A., Chieco P., Ravaioli M., Venturi A., et al. Aberrant Notch3 and Notch4 in human hepatocellular carcinoma. Liver International 27 (2007) 997-1007
14. Giovannini C., Lacchini M., Gramantieri L., Chieco P., and Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res 26 (2006) 2123-2127
15. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
16. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15 (2001) 188-200
17. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90 (1993) 8392-8396
18. Collins A.R. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26 (2004) 249-261
19. Iso T., Kedes L., and Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194 (2003) 237-255
20. Yu X., Alder J.K., Chun J.H., Friedman A.D., Heimfeld S., Cheng L., et al. HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells 24 (2006) 876-888
21. Nguyen M.H., and Keeffe E.B. General management. Best Pract Res Clin. Gastroenterol. 19 (2005) 161-174
22. Llovet J.M., and Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17 (2005) 505-513
23. Leong K.G., and Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 107 (2006) 2223-2233
24. O'Brien M.A., Moravec R.A., and Riss T.L. Poly (ADP-ribose) polymerase cleavage monitored in situ in apoptotic cells. Biotechniques 30 (2001) 886-891
25. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
26. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
27. Yan J., Yun H., Yang Y., Jing B., Feng C., and Song-bin F. Upregulation of BNIP3 promotes apoptosis of lung cancer cells that were induced by p53. Biochem Biophys Res Commun 346 (2006) 501-517
28. Thomas M.B., and Zhu A.X. Hepatocellular carcinoma: the need for progress. J Clin Oncol 23 (2005) 2892-2899
29. Grieco A., Pompili M., Caminiti G., Miele L., Covino M., Alfei B., et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54 (2005) 411-418
30. Gao J., Song Z., Chen Y., Xia L., Wang J., Fan R., et al. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis 40 (2008) 114-121